Bio-Rad Laboratories (BIO) drew fresh attention after CFO Roop K. Lakkaraju was slated for a fireside chat at the UBS Global Healthcare Conference, a forum investors often watch for management commentary.
Recent trading tells a mixed story for Bio-Rad Laboratories. The share price is US$372.18 after a 1-day share price return that declined 3.18%. However, the 90-day share price return of 14.35% and year-to-date share price return of 21.92% point to momentum that has been building over the medium term, even as the 5-year total shareholder return has fallen 48.71% and keeps longer term holders under water.
Compare Bio-Rad Laboratories with hand-picked peers by scanning our list of solid balance sheet and fundamentals (25 results) that have been holding up through mixed share price moves and shifting sector sentiment.
Short term strength at Bio-Rad Laboratories and a long term drawdown set up a simple fork in the road. Do you press in at today's price, or do you wait and hope for a cleaner entry?
Most Popular Narrative: 13% Overvalued
On the most followed valuation view, Bio-Rad Laboratories screens at a fair value of $329 against a last close of $372.18. That gap rests on modest revenue assumptions, steady but muted earnings, and a rich earnings multiple several years out.
Robust order growth and increased guidance in Bio-Rad's process chromatography business reflect the ongoing global investment in biopharmaceutical research and manufacturing, a trend likely to fuel sustainable double-digit revenue increases and improved operating leverage as new biologics and therapeutics expand the market.
See why 7 investors see Bio-Rad Laboratories as 13% overvalued .
Result: Fair Value of $329 (OVERVALUED)
Still, if instrument demand stays weak or Chinese diagnostics reimbursement tightens further, the Bio-Rad Laboratories overvaluation story could unravel much faster than expected.
Find out about the key risks to this Bio-Rad Laboratories narrative .
Next Steps
If this mix of short term strength and longer term pain around Bio-Rad Laboratories leaves you torn, rely on your own research and promptly test your thesis against the latest information by checking the 1 important warning sign .
Looking for more Bio-Rad Laboratories investment ideas?
Round out your view on Bio-Rad Laboratories by lining it up against fresh ideas that could sharpen your watchlist and keep your capital working harder.
-
Target potential mispricing and put quality front and center by scanning a focused group of 29 high quality undervalued stocks .
-
Build a steadier core to your holdings by searching for income opportunities across a curated set of 5 dividend fortresses .
-
Guard against unpleasant surprises and focus on resilience by filtering for 30 resilient stocks with low risk scores that still meet your quality bar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BIO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
